Celldex Therapeutics, Inc.

NasdaqCM:CLDX Rapport sur les actions

Capitalisation boursière : US$2.4b

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Celldex Therapeutics Gestion

Gestion contrôle des critères 2/4

Le PDG Celldex Therapeutics' est Anthony Marucci, nommé en May2003, a un mandat de 21.25 ans. La rémunération annuelle totale est $ 8.36M, composée du salaire de 8.6% et des bonus 91.4%, y compris les actions et options de la société. détient directement 0.043% des actions de la société, d'une valeur de $ 1.01M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 8.1 ans et 11.5 ans.

Informations clés

Anthony Marucci

Directeur général

US$8.4m

Rémunération totale

Pourcentage du salaire du PDG8.6%
Durée du mandat du directeur général21.3yrs
Propriété du PDG0.04%
Durée moyenne d'occupation des postes de direction8.1yrs
Durée moyenne du mandat des membres du conseil d'administration11.5yrs

Mises à jour récentes de la gestion

Here's Why Celldex Therapeutics, Inc.'s (NASDAQ:CLDX) CEO Compensation Is The Least Of Shareholders' Concerns

Jun 07
Here's Why Celldex Therapeutics, Inc.'s (NASDAQ:CLDX) CEO Compensation Is The Least Of Shareholders' Concerns

Recent updates

Here's Why Celldex Therapeutics, Inc.'s (NASDAQ:CLDX) CEO Compensation Is The Least Of Shareholders' Concerns

Jun 07
Here's Why Celldex Therapeutics, Inc.'s (NASDAQ:CLDX) CEO Compensation Is The Least Of Shareholders' Concerns

We Think Celldex Therapeutics (NASDAQ:CLDX) Can Afford To Drive Business Growth

Jun 05
We Think Celldex Therapeutics (NASDAQ:CLDX) Can Afford To Drive Business Growth

We Think Celldex Therapeutics (NASDAQ:CLDX) Can Afford To Drive Business Growth

Jul 07
We Think Celldex Therapeutics (NASDAQ:CLDX) Can Afford To Drive Business Growth

An Intrinsic Calculation For Celldex Therapeutics, Inc. (NASDAQ:CLDX) Suggests It's 34% Undervalued

Apr 21
An Intrinsic Calculation For Celldex Therapeutics, Inc. (NASDAQ:CLDX) Suggests It's 34% Undervalued

Companies Like Celldex Therapeutics (NASDAQ:CLDX) Are In A Position To Invest In Growth

Feb 27
Companies Like Celldex Therapeutics (NASDAQ:CLDX) Are In A Position To Invest In Growth

We're Not Very Worried About Celldex Therapeutics' (NASDAQ:CLDX) Cash Burn Rate

Sep 07
We're Not Very Worried About Celldex Therapeutics' (NASDAQ:CLDX) Cash Burn Rate

Celldex begins dosing in mid-stage study of barzolvolimab for skin disorder

Jul 21

Celldex: Barzolvolimab Plus Bispecific Antibodies Advancement

Jul 14

Celldex Therapeutics (NASDAQ:CLDX) Is In A Good Position To Deliver On Growth Plans

May 25
Celldex Therapeutics (NASDAQ:CLDX) Is In A Good Position To Deliver On Growth Plans

Are Investors Undervaluing Celldex Therapeutics, Inc. (NASDAQ:CLDX) By 31%?

Feb 03
Are Investors Undervaluing Celldex Therapeutics, Inc. (NASDAQ:CLDX) By 31%?

Celldex: Pipeline Of Drug Candidates Is Worth A Look

Feb 01

Celldex Therapeutics: A Best Price-Positioned Biotech Stock As Seen By Market-Makers

Sep 23

We Think Celldex Therapeutics (NASDAQ:CLDX) Can Easily Afford To Drive Business Growth

Sep 15
We Think Celldex Therapeutics (NASDAQ:CLDX) Can Easily Afford To Drive Business Growth

Celldex: Powerful Medicines To Yield Further Upsides

Jul 08

Here's Why We're Not Too Worried About Celldex Therapeutics' (NASDAQ:CLDX) Cash Burn Situation

May 12
Here's Why We're Not Too Worried About Celldex Therapeutics' (NASDAQ:CLDX) Cash Burn Situation

Analyse de la rémunération des PDG

Comment la rémunération de Anthony Marucci a-t-elle évolué par rapport aux bénéfices de Celldex Therapeutics?
DateRémunération totaleSalaireBénéfices de l'entreprise
Jun 30 2024n/an/a

-US$150m

Mar 31 2024n/an/a

-US$145m

Dec 31 2023US$8mUS$721k

-US$141m

Sep 30 2023n/an/a

-US$125m

Jun 30 2023n/an/a

-US$113m

Mar 31 2023n/an/a

-US$119m

Dec 31 2022US$5mUS$693k

-US$112m

Sep 30 2022n/an/a

-US$106m

Jun 30 2022n/an/a

-US$100m

Mar 31 2022n/an/a

-US$77m

Dec 31 2021US$6mUS$669k

-US$71m

Sep 30 2021n/an/a

-US$72m

Jun 30 2021n/an/a

-US$66m

Mar 31 2021n/an/a

-US$64m

Dec 31 2020US$3mUS$644k

-US$60m

Sep 30 2020n/an/a

-US$48m

Jun 30 2020n/an/a

-US$46m

Mar 31 2020n/an/a

-US$46m

Dec 31 2019US$1mUS$619k

-US$51m

Sep 30 2019n/an/a

-US$50m

Jun 30 2019n/an/a

-US$46m

Mar 31 2019n/an/a

-US$50m

Dec 31 2018US$1mUS$608k

-US$151m

Sep 30 2018n/an/a

-US$146m

Jun 30 2018n/an/a

-US$165m

Mar 31 2018n/an/a

-US$177m

Dec 31 2017US$2mUS$598k

-US$93m

Rémunération vs marché: La rémunération totale de Anthony ($USD 8.36M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 5.62M ).

Rémunération et revenus: La rémunération de Anthony a augmenté alors que l'entreprise n'est pas rentable.


PDG

Anthony Marucci (62 yo)

21.3yrs

Titularisation

US$8,361,844

Compensation

Mr. Anthony S. Marucci, M.B.A., has been the Chief Executive Officer and President of Celldex Therapeutics Inc. since September 2008. He co-founded Celldex Therapeutics Inc. in 2004. Mr. Marucci served as...


Équipe de direction

NomPositionTitularisationCompensationPropriété
Anthony Marucci
Founder21.3yrsUS$8.36m0.043%
$ 1.0m
Tibor Keler
Founder21.3yrsUS$3.42m0.011%
$ 263.1k
Sam Martin
Senior VP7.1yrsUS$2.95m0.042%
$ 1.0m
Margo Heath-Chiozzi
Senior Vice President of Regulatory Affairs6.8yrsUS$2.94m0.020%
$ 478.6k
Diane Young
Senior VP & Chief Medical Officer5.2yrsUS$2.97m0.026%
$ 612.0k
Joseph Schlessinger
Co-Founder & Member of Scientific Advisory Boardno datapas de donnéespas de données
Sarah Cavanaugh
Senior Vice President of Corporate Affairs & Administration7.2yrspas de données0.0028%
$ 66.6k
Freddy Jimenez
Senior VP & General Counsel3.6yrsUS$2.17m0.053%
$ 1.3m
Ronald Pepin
Chief Business Officer & Senior VP13.1yrsUS$1.36mpas de données
Elizabeth Crowley
Chief Product Development Officer & Senior VP10.1yrsUS$1.18m0.014%
$ 324.5k
Richard Wright
Chief Commercial Officer & Senior VP9.1yrsUS$563.17k0.031%
$ 745.0k

8.1yrs

Durée moyenne de l'emploi

62yo

Âge moyen

Gestion expérimentée: L'équipe de direction de CLDX est chevronnée et expérimentée (ancienneté moyenne 8.1 ans).


Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
Anthony Marucci
Founder15.7yrsUS$8.36m0.043%
$ 1.0m
Joseph Schlessinger
Co-Founder & Member of Scientific Advisory Board3yrspas de donnéespas de données
Harry Penner
Independent Director27.6yrsUS$371.19k0.0042%
$ 99.8k
Herbert Conrad
Independent Director16.4yrsUS$364.94k0.0039%
$ 91.7k
Louis Weiner
Member of Scientific Advisory Boardno datapas de donnéespas de données
James Marino
Independent Director7.4yrsUS$377.44k0.019%
$ 454.2k
Karen Shoos
Independent Chair of the Board of Directors23.3yrsUS$385.77k0.0042%
$ 99.6k
Carl June
Member of Scientific Advisory Boardno datapas de donnéespas de données
Michel Nussenzweig
Member of Scientific Advisory Boardno datapas de donnéespas de données
Marc Rothenberg
Member of Scientific Advisory Boardno datapas de donnéespas de données
Keith Brownlie
Independent Director7.2yrsUS$373.27k0.0010%
$ 23.7k
Cheryl Cohen
Independent Director2.2yrsUS$367.02k0%
$ 0

11.5yrs

Durée moyenne de l'emploi

72yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration CLDX sont chevronnés et expérimentés (durée moyenne d'administration 11.5 ans).